08:00 , Nov 16, 2015 |  BC Week In Review  |  Company News

Emisphere, Novo Nordisk deal

Emisphere granted Novo Nordisk worldwide rights to develop and commercialize oral formulations of four classes of Novo’s products, including those for diabetes and obesity, using Emisphere’s oral Eligen technology. Emisphere granted Novo exclusive rights to...
08:00 , Feb 23, 2015 |  BC Week In Review  |  Clinical News

Oral semaglutide: Phase II data

A double-blind, international Phase II trial in about 600 Type II diabetics showed that all 5 doses of once-daily oral semaglutide met the primary endpoint of reducing HbA1c from baseline to week 26 vs. placebo....
07:00 , Aug 19, 2013 |  BC Week In Review  |  Clinical News

Oral semaglutide: Phase I data

Novo Nordisk disclosed in its 2Q13 earnings that data from 5 Phase I trials in 400 healthy volunteers and 10 Type II diabetics showed that oral semaglutide was well tolerated. In a 10-week Phase I...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Clinical News

Oral PTH1-34 musculoskeletal data

Emisphere said that Novartis informed the company that data from a proof-of-concept trial in postmenopausal women with osteoporosis or osteopenia showed that oral PTH1-34 was well tolerated, but missed several undisclosed endpoints. Based on the...
07:00 , Oct 25, 2010 |  BioCentury  |  Regulation

Haunted by Byetta

Instead of a relatively small QTc study, Amylin Pharmaceuticals Inc. and Eli Lilly and Co. took a different tack - initially with FDA's blessing - that now looks likely to cost the partners at least...
07:00 , Jun 14, 2010 |  BC Week In Review  |  Company News

Emisphere, Novartis deal

Novartis cancelled a $10 million 7% convertible promissory note that was issued by Emisphere as part of a 2004 option deal for Novartis to license Emisphere's Eligen delivery technology to develop an oral formulation of...
07:00 , Apr 26, 2010 |  BC Week In Review  |  Clinical News

Oral PTH1-34: Phase I started

Novartis began a placebo-controlled Phase I trial in 120 postmenopausal women to compare oral PTH1-34 vs. Forteo teriparatide from Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.). Novartis licensed Emisphere's Eligen delivery technology to develop and...
07:00 , Oct 26, 2009 |  BC Week In Review  |  Clinical News

PTH1-34: Phase I data

In a Phase I trial in 32 healthy postmenopausal women, 2.5 and 5 mg oral PTH1-34 containing 200 mg 5-CNAC achieved exposure and safety profiles similar to that of 20 ug subcutaneous Forteo teriparatide from...
07:00 , Oct 19, 2009 |  BC Week In Review  |  Clinical News

Oral salmon calcitonin: Phase I data

In a double-blind Phase I trial in 73 patients, 0.6 and 0.8 mg of oral salmon calcitonin delivered by Emisphere's Eligen technology twice daily significantly reduced CTX-1 and CTX-11 levels vs. placebo at days 1...
08:00 , Dec 15, 2008 |  BC Week In Review  |  Company News

Emisphere drug delivery news

Emisphere restructured and reduced headcount by 40 (66%) to 21 to reduce costs. The company will close its Tarrytown, N.Y., research facility and use third-party contractors for preclinical testing of carrier molecules developed with its...